No Data
No Data
Individual Investors Are Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Biggest Owners and Were Hit After Market Cap Dropped CN¥686m
Anhui Anke Biotechnology (300009.SZ): Acetaminophen raw materials have received approval notices for listing applications.
On July 24th, Gelunhui reported that Anhui Anke Biotechnology (300009.SZ) announced that its wholly-owned subsidiary, Shanghai Suhao Yiming Pharmaceutical Co., Ltd., received the Approval Notice for the Marketing of Chemical Pharmaceutical Active Ingredients for Acetate Degarelix issued by the National Medical Products Administration and was publicly announced on the official website of the Medical Products Evaluation Center of the National Medical Products Administration. The joint approval result with the preparation is A, indicating that the API has met the qualification for market access in China. Acetate degarelix is a synthetic decapeptide, a gonadotropin-releasing hormone (GnRH) antagonist, which can competitively bind to pituitary cell membrane receptors with endogenous GnRH to inhibit its release.
Anhui Anke Biotechnology (300009.SZ): AFN0328 injection has obtained clinical trial approval for new indications.
On July 23, Gelunhui reported that Anke Biotechnology (300009.SZ) recently announced that Anhui Anke Biotechnology Engineering (Group) Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for the AFN0328 injection jointly declared by the company, its affiliate Hefei Alpharma Biotechnology Co., Ltd., and Hefei Alpharma Anke Biotechnology Co., Ltd., for the treatment of HPV16 and/or HPV18-related high-grade squamous intraepithelial lesions [HSIL] has been approved.
Anhui Anke Biotechnology Gets China Nod for HPV Injection Clinical Trials
Anhui Anke Biotechnology (300009.SZ): AFN0328 injection has obtained drug clinical trial approval.
On July 18th, Gelunhui reported that Anhui Anke Biotechnology (300009.SZ) recently received the Drug Clinical Trial Approval Notice issued by the National Drug Administration. The clinical trial application for "AFN0328 Injection" for the treatment of malignant tumors jointly filed by the company and its participating company Hefei Alphanate Biotechnology Co., Ltd. (hereinafter referred to as "Alphanate Company") and Hefei Alphanate Biotechnology Co., Ltd. has been approved. The Human Papillomavirus (HPV) belongs to the Papillomavirus.
Anhui Anke Biotechnology (300009.SZ): The terminal price of the injection of cetuximab, "Ansiteen" is 1575 yuan per vial.
On July 3, Gelunhui reported that Anhui Anke Biotechnology (300009.SZ) stated on the investor interactive platform that the terminal price of the injection of Trastuzumab 'Anzheqing' is 1575 yuan per vial, which is the lowest price among products of the same specification and type, and the current production capacity is sufficient.
No Data